Chemotherapy is a vital option for cancer treatment; however, its therapeutic outcomes are limited by dose-dependent toxicity and the occurrence of chemoresistance. siRNAs have emerged as an attractive therapeutic option enabling specific interference with target genes. Combination therapy using chemotherapeutic agents along with gene therapy could be a potential strategy for cancer management, which not only improves therapeutic efficacy but also decreases untoward effects from dose reduction. In this study, a cationic niosome containing plier-like cationic lipid B was used to convey siRNA against anti-apoptotic mRNA into MCF-7 and MDA-MB-231 cells. Mcl-1 silencing markedly decreased the viability of MCF-7 cells and triggered apoptosis. Moreover, computer modeling suggested that the combination of doxorubicin (Dox) and Mcl-1 siRNA exhibited a synergistic relationship and enabled a dose reduction of each agent at 1.71 and 3.91 folds, respectively, to reach a 90% inhibitory effect when compared to single-agent treatments. Synergistic antitumor activity was further verified in a 3D spheroid culture which revealed, in contrast to single-agent treatment, the combination markedly decreased spheroid volume over time. Together, the combination therapy between Mcl-1 silencing and Dox exhibits a synergistic effect that may be exploited for novel breast cancer treatment.

Breast cancer is the second leading cause of cancer-related death in the US. However, recurrence is frequently found despite adjuvant therapy being available. Combination therapy with cytotoxic drugs and gene therapy is being developed to be a new promising cancer treatment strategy. Introducing substituted dithiocarbamate moieties at the C12 position of andrographolide (3nAG) could improve its anticancer selectivity in the MCF-7 breast cancer cell line. However, its hydrophobicity is one of its main drawbacks. This work successfully prepared 3nAG nanosuspension stabilized with the chitosan derivative NSC (3nAGN-NSC) to increase solubility and pharmacological effectiveness. siRNAs have emerged as a promising therapeutic alternative for interfering with particular mRNA. The 3nAGN-NSC had also induced Mcl-1 mRNA expression in MCF-7 human breast cancer cells at 8, 12, and 24 h. This indicates that, in addition to Mcl-1 silencing by siRNA (siMcl-1) in MCF-7 with substantial Mcl-1 reliance, rationally devised combination treatment may cause the death of cancer cells in breast cancer. The Fa-CI analysis showed that the combination of 3nAGN-NSC and siMcl-1 had a synergistic effect with a combination index (CI) value of 0.75 (CI < 1 indicating synergistic effects) at the fractional inhibition of Fa 0.7. The synergistic effect was validated by flow cytometry, with the induction of apoptosis as the mechanism of reduced cell viability. Our findings suggested the rational use of 3nAGN-NSC in combination with siMcl-1 to kill breast cancer cells.

The challenge in HER2-overexpressing breast cancer therapy lies in creating an effective target therapy to overcome treatment resistance. Monoclonal antibodies and target gene silencing by siRNA are two potential strategies that have been widely developed for treating HER2-positive breast cancer. The siRNA delivery system is a crucial factor that influences siRNA therapy’s success. In this study, lipid-based nanoparticles (cationic niosomes) composed of different cholesterol-based cationic lipids were formulated and characterized for delivering siRNA into HER2-overexpressing breast cancer cells. Niosomes containing a trimethylammonium headgroup showed the highest siRNA delivery efficiency with low toxicity. The myeloid cell leukemia-1 (Mcl-1) siRNA nioplex treatment significantly decreased mRNA expression and breast cancer cell growth. Dual-targeted therapy, consisting of treatment with an Mcl-1 siRNA nioplex and trastuzumab (TZ) solution, noticeably promoted cell-growth inhibition and apoptosis. The synergistic effect of dual therapy was also demonstrated by computer modeling software (CompuSyn version 1.0). These findings suggest that the developed cationic niosomes were effective nanocarriers for siRNA delivery in breast cancer cells. Furthermore, the Mcl-1 nioplex/TZ dual treatment establishes a synergistic outcome that may have the potential to treat HER2-overexpressing breast cancer.

Background/Objectives: The purpose of this study was to create bile acid-containing liposomes to improve methotrexate blood-brain barrier penetration and to assess the liposome transportation mechanism across the blood–brain barrier. Methods: The improvement of liposome penetration was investigated utilizing human brain microvascular endothelial cells in an in vitro blood-brain barrier model. Using confocal laser scanning microscopy (CLSM) and flow cytometry, liposomes were labeled with fluorescent phospholipids to facilitate their passage across the blood–brain barrier. Results: The produced liposomes with bile acid exhibited a negative surface charge and an average particle size of between 30 and 148 nm. According to an in vitro blood-brain barrier penetration study, the methotrexate penetration was increased by liposomes containing 1% glycocholic acid but not by liposomes containing taurocholic acid. For transport pathway evaluation across the blood-brain barrier of these liposomes, CLSM revealed that fluorescent liposomes were present inside cells treated with specific endocytosis inhibitors, indicating that the cellular internalization of the particles was not involved in endocytosis. Conclusions: Liposomes supplemented with 1% glycocholic acid could enhance the penetration of methotrexate across the blood-brain barrier, while taurocholic acid could not. The transport of liposomes with 1% glycocholic acid across the blood-brain barrier occurs via the transcellular pathway through which it penetrates cells. In contrast, the paracellular pathway was a minor pathway.

Cationic lipid-based nanoparticulate systems are delivery systems that has been widely used in pharmaceutical field including gene delivery. There are many barriers obstructing genetic materials and their delivery systems to reach the target. Serum is one of the imperative factor that should be investigated. Therefore, the aim of this study was to examine the effect of serum on DNA protection ability of spermine-liposomes and niosomes by evaluating the percentage of transfection efficiency in Hela cell and observing the DNA degradation band using agarose gel electrophoresis in the presence of serum. The results showed that the percentage of transfection efficiency of spermine-liposomes was dramatically decreased when serum is presented (p< 0.05). In contrast, whether or not the serum is presented, the spermine-niosomes showed no significant difference in transfection efficiency. Concisely, liposomes could slightly protect DNA from DNase in the serum, whereas, niosomes had potential ability to protect DNA from the enzymes in serum. This result revealed an advantage of the cationic niosomes system as a gene carrier over the cationic liposomes.

Topical steroids are usually used for the treatment of inflammation and irritation of the skin; however, their inappropriate use results in serious side effects. Thus, the Thai Food and Drug Administration regulation forbade the use of corticosteroids in cosmetics. In this study, a method of high-performance liquid chromatography with a photodiode array detector was developed and validated for the simultaneous determination of three corticosteroids in cream formulation: triamcinolone acetonide (TA), betamethasone valerate (BV), and clobetasol propionate (CP). Chromatographic separation was performed on ACE® C18 (4.6 mm × 150 mm, 5 μm particle size) using a mobile phase consisting of water and acetonitrile in gradient elution. The detection wavelength was set at 254 and 240 nm. The validation results revealed the specificity and linearity of the proposed method with r≥0.999 within the concentration range of 2.5–50 μg/mL. The relative standard deviation (%) of the repeatability and intermediate precision of all corticosteroid samples at three different concentration levels were in the range of 0.04%–2.04% and 0.41%–4.93%, respectively, and the recovery (%) was 98.72 %–105.41%. The detection limits of TA, BV, and CP were 0.69, 0.46, and 0.48 μg/mL, respectively, and their quantitative limits were 2.08, 1.39, and 1.47 μg/mL, respectively. The validated method can be applied to quantify the amount of active compounds in commercial formulations and to determine the corticosteroid adulterants present in cream samples from online shops.